|1.||Buelow, Roland: 4 articles (09/2005 - 12/2003)|
|2.||Buelow, R: 4 articles (05/2003 - 02/2001)|
|3.||Iyer, Suhasini: 3 articles (09/2005 - 12/2003)|
|4.||Fong, Timothy: 3 articles (09/2005 - 04/2004)|
|5.||Luo, Yi: 2 articles (06/2008 - 02/2005)|
|6.||Lazarov, Mirella: 2 articles (09/2005 - 08/2005)|
|7.||Valdez, Marybeth: 2 articles (09/2005 - 07/2004)|
|8.||Belmar, Nicole: 2 articles (02/2005 - 04/2004)|
|9.||Evanoff, David P: 1 article (06/2008)|
|10.||Chen, Xiaohong: 1 article (06/2008)|
05/01/2003 - "The aims of this study were to investigate the anti-inflammatory properties of RDP58 ex vivo in human CD and in vivo in an experimental model colitis. "
11/01/2002 - "RDP58, a locally active TNF inhibitor, is effective in the dextran sulphate mouse model of chronic colitis."
05/01/2003 - "In rats with TNBS-induced colitis, oral RDP58 therapy reduced weight loss and diarrhoea and improved macroscopic and histological inflammation scores. "
11/01/2002 - "Orally administered RDP58 reduces the severity of dextran sodium sulphate induced colitis."
11/01/2002 - "RDP58 therapy was evaluated in the dextran sodium sulphate (DSS) model of chronic colitis. "
06/01/2008 - "In this study, we investigated whether RDP58 was effective as an intravesical agent for treating bladder autoimmune inflammation in a transgenic mouse model (URO-OVA mice). "
02/01/2001 - "The present study using Skh/hr hairless mouse skin model evaluated the in vivo effects of Allotrap 1258 on acute UVB-induced skin inflammation. "
06/01/2008 - "To determine whether the inhibition of bladder inflammation by RDP58 was due to the interference with effector T cells, we treated the cells with RDP58 in vitro. "
05/01/2003 - "Inflammation was assessed following 7 days of oral therapy with RDP58 or vehicle alone. "
11/01/2002 - "RDP58 significantly reduced acute, chronic and total inflammation scores. "
02/01/2005 - "In this study we evaluated the effects of intravesical RDP58 on an established model of cystitis. "
06/01/2008 - "Collectively, these results indicate that RDP58 is effective for treating T cell-mediated experimental autoimmune cystitis and may serve as a useful intravesical agent for the treatment of autoimmune-associated bladder inflammation such as IC."
06/01/2008 - "RDP58 inhibits T cell-mediated bladder inflammation in an autoimmune cystitis model."
08/01/2005 - "Re: Modulating bladder neuro-inflammation: RDP58, a novel anti-inflammatory peptide, decreases inflammation and nerve growth factor production in experimental cystitis."
02/01/2005 - "Modulating bladder neuro-inflammation: RDP58, a novel anti-inflammatory peptide, decreases inflammation and nerve growth factor production in experimental cystitis."
|4.||Weight Loss (Weight Reduction)
|5.||Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
|5.||Intercellular Signaling Peptides and Proteins (Growth Factors)
|7.||Protein Kinase C
|8.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|9.||Nerve Growth Factor (NGF)
|10.||Interleukin-12 (IL 12)
|4.||Homologous Transplantation (Allograft)
|5.||Drug Therapy (Chemotherapy)